Financiado en parte por Amgen, Pfizer, GlaxoSmithKline, Sanofi, Servier, Allergan
Serum 25-Hydroxyvitamin D Insufficiency in Search of a Bone Disease
Shah S, Chiang C, Sikaris K, Lu Z, Bui M, Zebaze R, Seeman E
The Journal of clinical endocrinology and metabolism · 46 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio de cohortes (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Amgen
- Empresa
- Pfizer
- Empresa
- GlaxoSmithKline
- Empresa
- Sanofi
- Empresa
- Servier
- Empresa
- Allergan
Según 6 financiadores declarados.
Publicación
- Publicado
- 2017-03-30 · J Clin Endocrinol Metab · vol. 102 · número 7 · págs. 2321–2328
- Editorial
- Oxford University Press
- Citado
- 49 citas · más que el 94% de estudios similares · 3.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 19 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Vitamin D Research Studies · Parathyroid Disorders and Treatments · Bone health and osteoporosis research
- Palabras clave
- Internal medicine, Endocrinology, N-terminal telopeptide, Parathyroid hormone, Bone remodeling, Vitamin D and neurology, vitamin D deficiency, Bone mineral, Osteoporosis, Hyperparathyroidism, Alkaline phosphatase, Hypophosphatemia, Bone resorption, Bone density, Calcium, Medicine, Secondary hyperparathyroidism, Chemistry, Osteocalcin, Biochemistry
- MeSH
- humans, bone diseases, vitamin d deficiency, phosphates, calcium, parathyroid hormone, alkaline phosphatase, vitamin d, glomerular filtration rate, cohort studies, bone remodeling, bone density, adult, aged, middle aged, victoria, female, male
7 autores
- Sonali S. Shah🇦🇺Austin Health
- Cherie Ying Chiang🇦🇺Austin Health
- Ken A. Sikaris🇦🇺Melbourne Clinic; Melbourne Health
- Zhong Xian Lu🇦🇺Melbourne Clinic; Melbourne Health
- Minh Bui🇦🇺The University of Melbourne
- Roger Martin Djoumessi Zebaze🇦🇺Austin Health
- Ego Seeman🇦🇺Austin Health; Australian Catholic University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Context
Vitamin D "insufficiency" and "deficiency" are defined as serum 25-hydroxyvitamin D [25(OH)D] levels <75 and <30 nmol/L, respectively. We aimed to determine whether these values signal hypocalcemia and hypophosphatemia, secondary hyperparathyroidism, high bone remodeling, low areal bone mineral density (aBMD), microstructural deterioration, or reduced matrix mineralization density (MMD) and so suggest whether bone fragility is present.
Methods
Concentrations of 25(OH)D, calcium, phosphate, creatinine, and parathyroid hormone (PTH) were measured in 11,855 participants. Serum C-terminal telopeptide of type 1 collagen, procollagen type 1 N-terminal propeptide (P1NP), aBMD, and distal radius microstructure and MMD were measured in a second subset of 150 participants.
Results
A breakpoint for calcium, PTH, and alkaline phosphatase was identified at a threshold 25(OH)D level <30 nmol/L. There was no plateau beyond 75 nmol/L. In the subgroup with measurements of bone morphology, no associations were detectable between serum 25(OH)D concentration, aBMD, trabecular density, cortical porosity, or MMD. Among 1439 participants with serum 25(OH)D <30 nmol/L, 6.1% had low serum calcium, 3.4% had low serum phosphate, 6.1% had high alkaline phosphatase, and 34.2% had elevated PTH. Most participants did not have any abnormalities.
Conclusion
At a 25(OH)D threshold of ≤30 nmol/L, abnormalities in biochemical features support the notion of a "deficiency" state predisposing to bone disease. However, no deleterious effects were found in participants within an insufficiency threshold of a 25(OH)D level of 30 to 75 nmol/L, which challenges the rationale justifying vitamin D supplementation in these individuals.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.